In many ways India, due to its population and the strength of its generic industry, is the key battlefield for global pharma in their war against cheaper generi

In many ways India, due to its population and the strength of its generic industry, is the key battlefield for global pharma in their war against cheaper generics. Which is why the Obama administration is trying to arm twist India into blocking generics: https://www.doctorswithoutborders.org/press/release.cfm?id=7077&cat=press-release#sthash.jVqHH7rr.dpuf https://www.doctorswithoutborders.org/press/release.cfm?id=7... http://jonathanturley.org/2013/09/26/obama-to-india-block-production-of-low-cost-generic-drugs-or-else/ http://jonathanturley.org/2013/09/26/obama-to-india-block-pr... India is also aggressively trying to reduce variation in drug prices within the country too. "Consumers will be the biggest beneficiaries as prices of some brands may fall by up to 70 per cent. [...] Analysts estimate that the policy will cover two-thirds of the Rs. 60,000 crore domestic industry. [...] The new policy differs from the existing DPCO 1995 in that it is based on the simple average price (SAP) for all brands with a market share above 1 per cent in their segment. The new policy also uses a market-based pricing mechanism against the earlier proposed cost-plus method. [...] In the long-term, the policy proposes to reduce the bandwidth of prices of the same molecule and this will have an impact on manufacturers in the mid and lower segments, analysts feel." http://www.thehindu.com/business/Industry/new-drug-price-regime-to-alter-structure/article4727977.ece?ref=relatedNews http://www.thehindu.com/business/Industry/new-drug-price-reg...